About Shanghai Kehua Bio-Engineering Co., Ltd.

        Shanghai Kehua Bio-engineering Co., Ltd (KHB), founded in 1981, is a high-tech enterprise with a complete industrial chain of in vitro diagnosis (IVD), integrating R&D, production and sales. The company was listed on the SMEs board of Shen Zhen Stock Exchange in China. Major businesses range from IVD reagents to diagnostic laboratory instruments. And as an R&D oriented high-tech enterprise, our company, based on its Biotechnology Innovation Center and postdoctoral research workstation, has established the R&D platforms of clinical IVD reagents and automatic laboratory instruments, to gradually advance the "serialization" and "integration" of reagents and instruments. In addition, our product line extension strategy has yielded remarkable results so far. For example, over a hundred products have been approved for production; 64 reagent and instrument products have been CE certified, main ones enjoying a certain reputation in the Chinese market; the company, while building an excellent marketing network across China, is also actively expanding the international market, for the Kehua-branded products have been exported to 38 countries and regions overseas; its AIDS diagnostic reagent has been included in the procurement catalog of some internationally renowned institutions, including the World Health Organization, the United Nations Children's Fund and the U.S. Presidential Foundation, and we have signed a long-term supply contract with the U.S. Clinton Foundation.

        With global thinking and local operation, we elaborate to achieve more. In the future, Kehua will continue to uphold its tenet - "care for life and commitment to excellence", value the foundation of talents, focus on specialization and internationalization, and rely on the capital market, to strive to build a brand of “KHB” that is renowned at both home and abroad, hence a long-lasting foundation. Kehua endeavors to create a long-term, sustainable value growth and performance for its customers and investors, and go all out for the full rise of China's laboratory medicine industry.